Drug
Kpl 716
Kpl 716: highest development phase Phase 2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| KPL-716 NCT03858634 | Phase 2 | Chronic Idiopathic Urticaria |
Latest
No recent events.
Follow Kpl 716 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.